Financials data is unavailable for this security.
View more
Year on year Shanghai Fosun Pharmaceutical Group Co Ltd 's revenues fell -5.81% from 43.95bn to 41.40bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 3.73bn to 2.39bn, a -36.04% decrease.
| Gross margin | 47.10% |
|---|---|
| Net profit margin | 6.63% |
| Operating margin | 7.38% |
| Return on assets | 2.44% |
|---|---|
| Return on equity | 4.54% |
| Return on investment | 4.18% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Shanghai Fosun Pharmaceutical Group Co Ltd fell by 1.67bn. However, the company earned 3.41bn from its operations for a Cash Flow Margin of 8.25%. In addition the company used 3.82bn on investing activities and also paid 1.34bn in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 17.71 |
|---|---|
| Tangible book value per share | 6.95 |
More ▼
Balance sheet in CNYView more
| Current ratio | 0.9203 |
|---|---|
| Quick ratio | 0.7221 |
| Total debt/total equity | 0.7524 |
|---|---|
| Total debt/total capital | 0.3755 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -35.71% and -37.54%, respectively. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 1.09% |
|---|---|
| Div growth rate (5 year) | -3.34% |
| Payout ratio (TTM) | 34.13% |
| EPS growth(5 years) | -3.54 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -40.81 |
More ▼
